67 related articles for article (PubMed ID: 36135813)
21. FOLFIRINOX Pharmacodynamic Interactions in 2D and 3D Pancreatic Cancer Cell Cultures.
Allen-Coyle TJ; Niu J; Welsch E; Conlon NT; Garner W; Clynes M; O'Sullivan F; Straubinger RM; Mager DE; Roche S
AAPS J; 2022 Oct; 24(6):108. PubMed ID: 36229752
[TBL] [Abstract][Full Text] [Related]
22. Monitoring Tumor Burden in Response to FOLFIRINOX Chemotherapy Via Profiling Circulating Cell-Free DNA in Pancreatic Cancer.
Wei T; Zhang Q; Li X; Su W; Li G; Ma T; Gao S; Lou J; Que R; Zheng L; Bai X; Liang T
Mol Cancer Ther; 2019 Jan; 18(1):196-203. PubMed ID: 30301865
[TBL] [Abstract][Full Text] [Related]
23. [Diagnostics and therapy of pancreatic carcinoma].
Wenzel P; von Figura G
Dtsch Med Wochenschr; 2021 Feb; 146(4):246-252. PubMed ID: 33592660
[TBL] [Abstract][Full Text] [Related]
24. Nal-IRI/5-FU/LV versus modified FOLFIRINOX and FOLFIRI as second-line chemotherapy for unresectable pancreatic cancer: A single center retrospective study.
Tezuka S; Ueno M; Kobayashi S; Hamaguchi T; Yamachika Y; Oishi R; Nagashima S; Fukushima T; Morimoto M; Shin M
Pancreatology; 2022 Sep; 22(6):789-796. PubMed ID: 35705458
[TBL] [Abstract][Full Text] [Related]
25. Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older.
Mizrahi JD; Rogers JE; Hess KR; Wolff RA; Varadhachary GR; Javle MM; Shroff RT; Ho L; Fogelman DR; Raghav KPS; Overman MJ; Pant S
Pancreatology; 2020 Apr; 20(3):501-504. PubMed ID: 31932214
[TBL] [Abstract][Full Text] [Related]
26. Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer.
Chiang NJ; Chang JY; Shan YS; Chen LT
Expert Opin Pharmacother; 2016 Jul; 17(10):1413-20. PubMed ID: 27140876
[TBL] [Abstract][Full Text] [Related]
27. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma.
Hosein PJ; Macintyre J; Kawamura C; Maldonado JC; Ernani V; Loaiza-Bonilla A; Narayanan G; Ribeiro A; Portelance L; Merchan JR; Levi JU; Rocha-Lima CM
BMC Cancer; 2012 May; 12():199. PubMed ID: 22642850
[TBL] [Abstract][Full Text] [Related]
28. Patient-tailored FOLFIRINOX as first line treatment of patients with advanced pancreatic adenocarcinoma.
Ulusakarya A; Teyar N; Karaboué A; Haydar M; Krimi S; Biondani P; Gumus Y; Chebib A; Almohamad W; Morère JF
Medicine (Baltimore); 2019 Apr; 98(16):e15341. PubMed ID: 31008993
[TBL] [Abstract][Full Text] [Related]
29. FOLFIRINOX for locally advanced pancreatic cancer: Results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japan.
Matsumoto I; Kamei K; Omae K; Suzuki S; Matsuoka H; Mizuno N; Ozaka M; Ueno H; Kobayashi S; Uesugi K; Kobayashi M; Todaka A; Fukutomi A
Pancreatology; 2019 Mar; 19(2):296-301. PubMed ID: 30638853
[TBL] [Abstract][Full Text] [Related]
30. A single microbubble formulation carrying 5-fluorouridine, Irinotecan and oxaliplatin to enable FOLFIRINOX treatment of pancreatic and colon cancer using ultrasound targeted microbubble destruction.
Gao J; Logan KA; Nesbitt H; Callan B; McKaig T; Taylor M; Love M; McHale AP; Griffith DM; Callan JF
J Control Release; 2021 Oct; 338():358-366. PubMed ID: 34481018
[TBL] [Abstract][Full Text] [Related]
31. Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline and locally advanced pancreatic adenocarcinoma: An AGEO multicentric retrospective cohort.
Kourie H; Auclin E; Cunha AS; Gaujoux S; Bruzzi M; Sauvanet A; Lourenco N; Trouilloud I; Louafi S; El-Hajjar A; Vaillant JC; Smith D; Touchefeu Y; Bachet JB; Pietrasz D; Taieb J
Clin Res Hepatol Gastroenterol; 2019 Nov; 43(6):663-668. PubMed ID: 31029644
[TBL] [Abstract][Full Text] [Related]
32. A new pancreatic adenocarcinoma-derived organoid model of acquired chemoresistance to FOLFIRINOX: First insight of the underlying mechanisms.
Hadj Bachir E; Poiraud C; Paget S; Stoup N; El Moghrabi S; Duchêne B; Jouy N; Bongiovanni A; Tardivel M; Weiswald LB; Vandepeutte M; Beugniez C; Escande F; Leteurtre E; ; Poulain L; Lagadec C; Pigny P; Jonckheere N; Renaud F; Truant S; Van Seuningen I; Vincent A
Biol Cell; 2022 Jan; 114(1):32-55. PubMed ID: 34561874
[TBL] [Abstract][Full Text] [Related]
33. Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience.
Glassman DC; Palmaira RL; Covington CM; Desai AM; Ku GY; Li J; Harding JJ; Varghese AM; O'Reilly EM; Yu KH
BMC Cancer; 2018 Jun; 18(1):693. PubMed ID: 29945562
[TBL] [Abstract][Full Text] [Related]
34. Irreversible electroporation after induction chemotherapy versus chemotherapy alone for patients with locally advanced pancreatic cancer: A propensity score matching analysis.
He C; Wang J; Zhang Y; Lin X; Li S
Pancreatology; 2020 Apr; 20(3):477-484. PubMed ID: 32131993
[TBL] [Abstract][Full Text] [Related]
35. FOLFIRINOX De-Escalation in Advanced Pancreatic Cancer: A Multicenter Real-Life Study.
Chevalier H; Vienot A; Lièvre A; Edeline J; El Hajbi F; Peugniez C; Vernerey D; Meurisse A; Hammel P; Neuzillet C; Borg C; Turpin A
Oncologist; 2020 Nov; 25(11):e1701-e1710. PubMed ID: 32886823
[TBL] [Abstract][Full Text] [Related]
36. Systemic Combination Chemotherapy in Elderly Pancreatic Cancer: a Review.
Garcia G; Odaimi M
J Gastrointest Cancer; 2017 Jun; 48(2):121-128. PubMed ID: 28303435
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and Toxicity of Different Chemotherapy Regimens in the Treatment of Advanced or Metastatic Pancreatic Cancer: A Network Meta-Analysis.
Liu GF; Li GJ; Zhao H
J Cell Biochem; 2018 Jan; 119(1):511-523. PubMed ID: 28608558
[TBL] [Abstract][Full Text] [Related]
38. Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients.
Sugimoto M; Takagi T; Suzuki R; Konno N; Asama H; Sato Y; Irie H; Okubo Y; Nakamura J; Takasumi M; Hashimoto M; Kato T; Kobashi R; Hikichi T; Ohira H
BMC Cancer; 2021 Dec; 21(1):1319. PubMed ID: 34886831
[TBL] [Abstract][Full Text] [Related]
39. Patient-derived Organoid Model for Predicting the Chemoresponse in Patients With Colorectal Cancer.
Yi K; Park SH; Kim DU; Jeon DY; Lee HJ; Song GA; Jo HJ; Baek DH; Han JH; Lee BC
In Vivo; 2023; 37(4):1751-1759. PubMed ID: 37369516
[TBL] [Abstract][Full Text] [Related]
40. Preclinical Synergistic Combination Therapy of Lurbinectedin with Irinotecan and 5-Fluorouracil in Pancreatic Cancer.
Tummala T; Sevilla Uruchurtu AS; Cruz A; Huntington KE; George A; Liguori NR; Zhang L; Zhou L; Abbas AE; Azzoli CG; El-Deiry WS
Curr Oncol; 2023 Oct; 30(11):9611-9626. PubMed ID: 37999116
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]